Comparison of seven immunoassays for the quantification of CA 125 antigen in serum

Abstract

Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were determined in 289 serum samples obtained from women with benign pelvic tumors (samples from 98 patients) and patients with various cancers (samples from 111 patients). In the range of 0–1000 kilounits/L, all assays tested were linearly correlated, with correlation coefficients ranging from 0.89 to 0.99. In relation to the original Centocor CA 125 assay, there was an overall tendency to measure higher absolute values in the lower CA 125 value range. This was not seen in relation to the Centocor CA 125 II assay. ROC curves (benign vs pretreatment ovarian cancer patients) were nearly identical for all assays, and the areas under the ROC curves were not markedly different. We conclude that the CA 125 assays tested are strongly related to each other and are clinically reliable for the quantification of serum CA 125 and that none of the assays offers higher diagnostic accuracy or better discrimination between patient groups, especially not in the lower ranges.

Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray‐scale and Doppler ultrasound findings: logistic regression models do not help

“…Another limitation of our study was that different CA 125 kits were used to assess the level of serum CA 125. However, this reflects clinical reality, and there is some evidence that the variation in CA 125 resulting from the use of different kits is not large22, 23.…”

Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses

“…Another limitation of our study is that five CA 125 kits were used to assess the level of serum CA 125. However, this reflects clinical reality, and there is some evidence that the variation in CA 125 resulting from use of different kits is not large23, 24.…”

Electrochemical impedence spectroscopy enabled CA125 detection; toward early ovarian cancer diagnosis using graphene biosensors

“…A CA125 enzyme‐linked immunoassays kit is also available from Phoenix Pharmaceuticals, which detects a minimum concentration of 5 U/mL using horseradish peroxidase. Assays from a variety of manufacturers have been compared by Davelaar et al (Davelaar, Kamp, Verstraeten, & Kenemans, ). Commercially available multi‐analyte tests include immunoradiometric assays, enzyme‐linked immunoassays, and chemiluminescent microparticle immunoassay provided by a range of companies and have been extensively compared by Sharma et al (Kenemans, Verstraeten, Vankamp, & Vonmensdorffpouilly, ; Sharma, Raghav, O'Kennedy, & Srivastava, ).…”